GTX-102's Phase 3 wipeout forces Ultragenyx to restructure around GENGLYCOS revenue and a Sanfilippo gene therapy that already drew one CRL

Ultragenyx is a commercial-stage rare-disease company with two approved products, including GENGLYCOS for a genetic glycogen storage disorder, while its pipeline centers on UX111, a gene therapy for Sanfilippo syndrome that is not yet approved and has already received one rejection from the FDA.

Built around a rare-disease gene therapy pipeline, Ultragenyx absorbed a 47% stock collapse when GTX-102 failed its Phase 3 primary endpoint in Angelman syndrome with no efficacy signal across any treated group. What remains is GENGLYCOS, an accelerated-approval gene therapy for GSDIa generating early commercial revenue, and UX111, a resubmitted Sanfilippo gene therapy facing a PDUFA decision after a prior CRL and an incomplete response letter. The UX111 resubmission rests on a single-arm dataset that FDA has already rejected once, making approvability the central unresolved question for a company burning roughly $97 million per quarter.